Autologous Transplantation with CD52 Monoclonal Antibody-Purged Marrow for Acute Lymphoblastic Leukemia: Long-Term Follow-Up

References

• Hoelzer D., Gale R. P. Acute lymphoblastic leukemia in adults: recent progress, future directions. Semin. Hematol. 1987; 24: 27–39
   PubMed Web of Science ®Google Scholar
• Barnett M. J., Greaves M. F., Amess J. A., et al. Treatment of acute lymphoblastic leukaemia in adults. Br. J. Haemalol. 1986; 64: 455–468
   PubMed Web of Science ®Google Scholar
• Hoelzer D., Thiel E., Löffler H., et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123–131
   PubMed Web of Science ®Google Scholar
• Hussein K. K., Dahlberg S., Head D., et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 1989; 73: 57–63
   PubMed Web of Science ®Google Scholar
• Linker C. A., Levitt L. J., O'Donnell M., Forman S. J., Ries C. A. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow‐up report. Blood 1991; 78: 2814–2822
   PubMed Web of Science ®Google Scholar
• Horowitz M. M., Messerer D., Hoelzer D., et al. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann. Intern. Med. 1991; 115: 13–18
   PubMed Web of Science ®Google Scholar
• Dicke K. A. Role of bone marrow transplant in acute lymphocytic leukemia. Leukemia 1992; 6(Suppl 4)56–58
   PubMedGoogle Scholar
• Weisdorf D. J., Nesbit M. E., Ramsay N. K., et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associated with acute graft‐versus‐host disease. J. Clin. Oncol 1987; 5: 1348–1355
   PubMed Web of Science ®Google Scholar
• Doney K., Fisher L. D., Appelbaum F. R., et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft‐versus‐host disease, relapse, and relapse‐free survival. Bone Marrow Transplant. 1991; 7: 453–459
   PubMed Web of Science ®Google Scholar
• Chao N. J., Forman S. J., Schmidt G. M., et al. Allogeneic bone marrow transplantation for high‐risk acute lymphoblastic leukemia during first complete remission. Blood 1991; 78: 1923–1927
   PubMed Web of Science ®Google Scholar
• Wingard J. R., Piantadosi S., Santos G. W., et al. Allogeneic bone marrow transplantation for patients with high‐risk acute lymphoblastic leukemia. J. Clin. Oncol. 1990; 8: 820–830
   PubMed Web of Science ®Google Scholar
• Blaise D., Gaspard M. H., Stoppa A. M., et al. Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant 1990; 5: 7–12
   PubMed Web of Science ®Google Scholar
• Gilmore M. J.M. L., Hamon M. D., Prentice H. G., et al. Failure of purged autologous bone marrow transplantation in high risk acute lymphoblastic leukaemia in first complete remission. Bone Marrow Transplant. 1991; 8: 19–26
   PubMed Web of Science ®Google Scholar
• Here D., Lepage E., Sebban C., et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. J. Clin. Oncol. 1993; 10: 1990–2001
   Google Scholar
• Tiley C., Powles R., Treleaven J., et al. Feasibility and efficacy of maintenance chemotherapy following autologous bone marrow transplantation for first remission acute lymphoblastic leukaemia. Bone Marrow Transplant. 1993; 12: 449–455
   PubMed Web of Science ®Google Scholar
• Powles R., Mehta J., Singhal S., et al. Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission: 50 cases from a single center. Bone Marrow Transplant. 1995; 16: 241–247
   PubMed Web of Science ®Google Scholar
• Ritz J., Sallan S. E., Bast R. C., et al. Autologous bone‐marrow transplantation in CALLA‐positive acute lymphoblastic leukemia after in‐vitro treatment with J5 monoclonal antibody and complement. Lancet 1982; 2: 60–63
   PubMed Web of Science ®Google Scholar
• Kersey J. H., Weisdorf D., Nesbit M. E., et al. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high‐risk refractory acute lymphoblastic leukemia. N. Engl. J. Med. 1987; 317: 461–467
   PubMed Web of Science ®Google Scholar
• Preijers F. W., De Witte T., Wessels J. M., et al. Autologous transplantation of bone marrow purged in vitro with anti‐CD7‐(WT1‐) ricin A immunotoxin in T‐cell lymphoblastic leukemia and lymphoma. Blood 1989; 74: 1152–1158
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Kersey J. H., Vallera D. A., et al. Autologous bone marrow transplantation in high‐risk remission T‐lineage acute lymphoblastic leukemia using immuno‐toxins plus 4‐hydroperoxycyclophosphamide for marrow purging. Blood 1990; 76: 1723–1733
   PubMed Web of Science ®Google Scholar
• Yeager A. M., Rowley S. D., Kaizer H., Santos G. W. Ex vivo chemopurging of autologous bone marrow with 4–hydroperoxycyclophosphamide to eliminate occult leukemic cells. Laboratory and clinical observations. Am. J. Pediatr. Hematol. Oncol 1990; 12: 245–256
   PubMedGoogle Scholar
• Uckun F. M., Kersey J. H., Haake R., Weisdorf D., Ramsay N. K. Autologous bone marrow transplantation in high‐risk remission B‐lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA‐1/CD24, BA‐2/CD9, and BA‐3/CD10) plus complement and 4‐hydroperoxycyclophosphamide for ex vivo bone marrow purging. Blood 1992; 79: 1094–1104
   PubMed Web of Science ®Google Scholar
• Billett A. L., Kornmehl E., Tarbell N. J., et al. Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. Blood 1993; 81: 1651–1657
   PubMed Web of Science ®Google Scholar
• Schmid H., Henze G., Schwerdtfeger R., et al. Fractionated total body irradiation and high‐dose VP‐16 with purged autologous bone marrow rescue for children with high risk relapsed acute lymphoblastic leukemia. Bone Marrow Transplant. 1993; 12: 597–602
   PubMed Web of Science ®Google Scholar
• Laporte J. P., Douay L., Lopez M., et al. One hundred twenty‐five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10‐year single institution experience. Blood 1994; 84: 3810–3818
   PubMed Web of Science ®Google Scholar
• Hale G., Bright S., Chumbley G., et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983; 62: 873–882
   PubMed Web of Science ®Google Scholar
• Hale G., Waldmann H. CAMPATH‐1 monoclonal antibodies in bone marrow transplantation. J. Hematother. 1994; 3: 15–31
   PubMedGoogle Scholar
• Gazitt Y., Or R., Mumcuoglu M., Slavin S. Monoclonal rat anti‐human lymphocyte antibody Campath‐1 binds to T and B lymphocytes but effectively lyses only T cells. Bone Marrow Transplant. 1987; 2: 427–433
   PubMed Web of Science ®Google Scholar
• Naparstek E., Or R., Nagler A., et al. T‐cell‐depleted allogeneic bone marrow transplantation for acute leukaemia using Campath‐1 antibodies and post‐transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br. J. Haematol 1995; 89: 506–515
   PubMed Web of Science ®Google Scholar
• Hale G., Swirsky D., Waldmann H., Chan L. C. Reactivity of rat monoclonal antibody CAMPATH‐1 with human leukaemia cells and its possible application for autologous bone marrow transplantation. Br. J. Haematol. 1985; 60: 41–48
   PubMed Web of Science ®Google Scholar
• Hale G., Dyer M. J. S., Clark M. R., et al. Remission induction in non‐Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH‐1H. Lancet 1988; 2: 1394–1399
   PubMed Web of Science ®Google Scholar
• Dyer M. J. S., Hale G., Hayhoe F. G., Waldmann H. Effects of CAMPATH‐1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73: 1431–1439
   PubMed Web of Science ®Google Scholar
• Yeager A. M., Kaizer H., Santos G. W., et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4‐hydroperoxycyclophosphamide. N. Engl. J. Med. 1986; 315: 141–147
   PubMed Web of Science ®Google Scholar
• Gorin N. C., Labopin M., Meloni G., et al. Autologous bone marrow transplantation for acute myeloblas‐tic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. European Co‐operative Group for Bone Marrow Transplantation (EBMT). Leukemia 1991; 5: 896–904
   PubMed Web of Science ®Google Scholar
• Mehta J., Powles R., Horton C., Treleaven J., Singhal S. Factors affecting engraftment and hematopoietic recovery after unpurged autografting in acute leukemia. Bone Marrow Transplant. 1996; 18: 319–324
   PubMed Web of Science ®Google Scholar
• Mehta J. Graft‐versus‐leukemia reactions in clinical bone marrow transplantation. Leuk. Lymphoma 1993; 10: 427–432
   PubMed Web of Science ®Google Scholar
• Brenner M. K., Rill D. R., Moen R. C., et al. Gene‐marking to trace origin of relapse after autologous bone‐marrow transplantation. Lancet 1993; 341: 85–86
   PubMed Web of Science ®Google Scholar
• Hale G., Waldmann H. Availability of Campath‐1 antibodies for bone marrow transplantation. Bone Marrow Transplant. 1995; 15: 327
   PubMed Web of Science ®Google Scholar
• Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323–327
   PubMed Web of Science ®Google Scholar